VOTRIENT pazopanib hydrochloride tablet film coated United States - English - NLM (National Library of Medicine)

votrient pazopanib hydrochloride tablet film coated

glaxosmithkline llc - pazopanib hydrochloride (unii: 33y9anm545) (pazopanib - unii:7rn5dr86ck) - pazopanib 200 mg

Pazopanib Pharmacare 200 mg film-coated tablets Malta - English - Medicines Authority

pazopanib pharmacare 200 mg film-coated tablets

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - film-coated tablet - pazopanib 200 mg - antineoplastic agents

Pazopanib Pharmacare 400 mg film-coated tablets Malta - English - Medicines Authority

pazopanib pharmacare 400 mg film-coated tablets

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - film-coated tablet - pazopanib 400 mg - antineoplastic agents

VOTRIENT pazopanib 200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

votrient pazopanib 200 mg tablet bottle

novartis pharmaceuticals australia pty ltd - pazopanib hydrochloride, quantity: 216.7 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - votrient is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (rcc). votrient is indicated for the treatment of patients with advanced (unresectable and/or metastatic) soft tissue sarcoma (sts) in patients who, unless otherwise contraindicated, have received prior chemotherapy including an anthracycline treatment. the phase iii trial population excluded patients with gastrointestinal stromal tumour (gist) or adipocytic soft tissue sarcoma.

VOTRIENT pazopanib 400 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

votrient pazopanib 400 mg tablet bottle

novartis pharmaceuticals australia pty ltd - pazopanib hydrochloride, quantity: 433.4 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - votrient is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (rcc). votrient is indicated for the treatment of patients with advanced (unresectable and/or metastatic) soft tissue sarcoma (sts) in patients who, unless otherwise contraindicated, have received prior chemotherapy including an anthracycline treatment. the phase iii trial population excluded patients with gastrointestinal stromal tumour (gist) or adipocytic soft tissue sarcoma.

Votrient Tablet 200 mg Singapore - English - HSA (Health Sciences Authority)

votrient tablet 200 mg

novartis (singapore) pte ltd - pazopanib hydrochloride 216.7 mg eqv pazopanib - tablet, film coated - 200 mg - pazopanib hydrochloride 216.7 mg eqv pazopanib 200 mg

Votrient Tablet 400 mg Singapore - English - HSA (Health Sciences Authority)

votrient tablet 400 mg

novartis (singapore) pte ltd - pazopanib hydrochloride 433.4 mg eqv pazopanib - tablet, film coated - 400 mg - pazopanib hydrochloride 433.4 mg eqv pazopanib 400 mg

VOTRIENT TABLET Canada - English - Health Canada

votrient tablet

novartis pharmaceuticals canada inc - pazopanib (pazopanib hydrochloride) - tablet - 400mg - pazopanib (pazopanib hydrochloride) 400mg - antineoplastic agents

Pazopanib EG 200 mg film-coat. tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pazopanib eg 200 mg film-coat. tabl.

eg sa-nv - pazopanib hydrochloride 216,7 mg - eq. pazopanib 200 mg - film-coated tablet - pazopanib

Pazopanib EG 400 mg film-coat. tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pazopanib eg 400 mg film-coat. tabl.

eg sa-nv - pazopanib hydrochloride 433,4 mg - eq. pazopanib 400 mg - film-coated tablet - pazopanib